Your browser doesn't support javascript.
loading
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza, M R; Coleman, R L; González-Martín, A; Moore, K N; Colombo, N; Ray-Coquard, I; Pignata, S.
Afiliação
  • Mirza MR; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: Mansoor.Raza.Mirza@regionh.dk.
  • Coleman RL; Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
  • González-Martín A; Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
  • Moore KN; Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, USA.
  • Colombo N; Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy.
  • Ray-Coquard I; Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
  • Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Ann Oncol ; 31(9): 1148-1159, 2020 09.
Article em En | MEDLINE | ID: mdl-32569725
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article